NKNatalie R. Klug

Natalie R. Klug

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalie R. Klug has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preserving Nanotherapy-Induced Allogeneic Murine Islet Graft Tolerance During Distal Methicillin-Resistant Staphylococcus aureus Skin Infection

    by El Hadji Arona Mbaye, Debora B. Scariot, Xiaomin Zhang, Calleigh P. Reber, Natalie R. Klug, Szumo Wang, Sultan Almunif, Amanda B. K. Bakoshi, Rayanne R. M. Machado, Natalia C. Mendoca, et al.

    Eliminating lifelong immunosuppression can make islet transplantation a durable alternative to insulin therapy for type 1 diabetes. As short-course tolerogenic regimens are developed to replace lifelong immunosuppression, it is critical to test their robustness against perturbations such as hospital-acquired infections, which transplant recipients routinely encounter. Herein, we investigated whether rapamycin-loaded polymersomes (rPS), a subcutaneous nanotherapy that induces long-term murine islet allograft survival, can preserve host defenses in a Methicillin-resistant Staphylococcus aureus (MRSA) skin infection, and whether the resulting immune response from this distal infection relative to graft location erodes rPS-induced tolerance. rPS maintained neutrophil antibacterial activity despite inhibiting oxidative mechanisms in vitro, and rPS-treated mice demonstrated normal recovery following MRSA challenge. However, MRSA skin infection caused a decline of ~43% in recipient survival for rPS-treated mice, despite surviving recipients retaining glucose-stimulated insulin responsiveness. This erosion of allograft acceptance coincided with a burst of IL-6 within 24h of the infection followed by elevated TNF-ɑ and neutrophilia at 13 days post-infection. Combining rPS with a single dose of methylprednisolone reduced IL-6 and TNF-α without altering neutrophilia, nearly doubling survival among infected recipients to 80%. Our findings demonstrate that partial dampening of inflammatory insults can restore superior islet allograft acceptance following perioperative infection.

  • Open Access

    Nanotherapy-mediated biased antigen-presenting cell reprogramming supports T cell anergy to prevent type 1 diabetes

    by Natalie R. Klug, El Hadji Arona Mbaye, Szumo Wang, Sultan Almunif, C. Ramsey Grace, Joseph W. Reda, Débora B. Scariot, Simseok A. Yuk, Yu-Gang Liu, Drew H. Landrowski, et al.

    Summary: Engineering immune tolerance using endogenously expressed autoantigens could enable early intervention in autoimmune disease. Present therapies suppress T cells to slow disease progression. Here, we develop rapamycin-loaded poly(ethylene glycol)- b -poly(propylene sulfide) polymersomes (rPS) to modulate antigen-presenting cells (APCs) during disease-associated antigen presentation. The rPS morphology enables lymphatic drainage following subcutaneous administration to access APCs in draining lymph nodes. Treatment reduced APC costimulatory marker coexpression and shifted CD4⁺ T cells toward an FR4 hi CD73 hi anergic phenotype. In a type 1 diabetes (T1D) nonobese diabetic (NOD) mouse model, rPS significantly delayed disease onset relative to the standard of care and selectively prevented hyperglycemia. Mediation via APCs, rPS avoids adverse effects including transient lymphopenia. These findings demonstrate how biomaterial-directed drug delivery can reshape APC–T cell interactions, supporting an antigen-agnostic strategy for delaying autoimmune diabetes without systemic lymphocyte depletion. The bigger picture: Type 1 diabetes (T1D) results from a complex autoimmune attack on insulin-producing pancreatic β cells. While the detection of islet autoantibodies before T1D onset enables the development of early intervention strategies, the temporal dynamics of islet antigen presentation and the full repertoire of relevant islet antigens remain unclear. Current immunotherapies primarily target T cells to halt islet injury but can cause transient systemic immune suppression and are not curative. Herein, we identify a potential new therapeutic strategy by which antigen-presenting cells (APCs) are reprogrammed to arrest T1D progression without systemic lymphodepletion. To this end, we utilize rapamycin-loaded polymersome (rPS) nanocarriers which selectively deliver the rapamycin payload to APCs. When given prior to disease onset, rPS treatment delays and prevents hyperglycemia in comparison to a T cell-directed, antibody-mediated systemic therapy. Importantly, our study provides a comprehensive evaluation of therapeutic intervention and disease progression. Through subcutaneous injection, the nanotherapeutic approach leverages lymphatic drainage to reach the draining lymph nodes. Here, rPS-induced costimulation-deficient APCs can prevent T cell activation without supplying a specific antigen in prediabetic mice. Complex immunoprofiling validated APC reprogramming in vivo and characterized T cell activation state in presymptomatic mice. Overall, this novel biomaterial-mediated approach demonstrates the importance of designing early intervention therapies to disrupt the T cell activation pathway and offer protection to functional β cells and an opportunity to achieve long-term insulin independence. Highlights: Rapamycin-loaded polymersomes (rPS) are an APC-directed nanotherapy to slow T1D progression A short course of subcutaneous (SC) rPS therapy delays T1D onset in early prediabetic mice APC-mediated reprogramming halts T1D progression without lymphodepletion Maintenance of effector-memory CD4+ T cell anergy is critical to prevent hyperglycemia Graphical

  • Open Access

    Engineering the Size of Bicontinuous Nanospheres via Multi-Inlet Vortex Mixing

    by Sultan Almunif, Simseok A. Yuk, El Hadji Arona Mbaye, Swagat Sharma, Michael D. Purdy, Sandeep Kumar, Natalie R. Klug, Evan A. Scott

    Bicontinuous nanospheres (BCNs) are self-assembled nanostructures with interconnected aqueous channels that enable the coloading of hydrophilic and hydrophobic cargo; however, their size has been difficult to control. Here, we present a scalable approach to tune the size distribution of poly(ethylene glycol)-b-poly(propylene sulfide) BCNs using a multi-inlet vortex mixer. Higher mixing times and polymer concentrations produced larger BCNs, while shorter mixing times and lower concentrations yielded spherical micelles. Small-angle X-ray scattering and cryogenic transmission electron microscopy confirmed the BCN bicontinuous morphology, which persisted at smaller sizes. The porous BCN structure resulted in increased surface roughness compared to polymersomes (PSs). In vitro, BCNs and PSs of comparable sizes recruited distinct protein coronas early, but their profiles showed convergence by 24 h. In vivo, organ biodistribution was determined primarily by the nanocarrier size rather than the morphology. These findings establish a robust approach to BCN fabrication while revealing dynamic biological interactions that inform nanocarrier design.


  • Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation

    by Natalie Klug, Jacqueline Burke, Evan Scott

    Type 1 diabetes (T1D) onset is characterized by an autoimmune attack on β islet cells within the pancreas, preventing the insulin secretion required to maintain glucose homeostasis. Targeted modulation of key immunoregulatory cell populations is a promising strategy to restore tolerance to β cells. This strategy can be used to prevent T1D onset or reverse T1D with transplanted islets. To this end, drug delivery systems can be employed to transport immunomodulatory cargo to specific cell populations that inhibit autoreactive T cell–mediated destruction of the β cell mass. The rational engineering of biomaterials into nanoscale and microscale drug carriers can facilitate targeted interactions with immune cells. The physicochemical properties of the biomaterial, the delivered immunomodulatory agent, and the target cell populations are critical variables in the design of these delivery systems. In this review, we discuss recent biomaterials-based drug delivery approaches to induce islet tolerance and the need to consider both immune and metabolic markers of disease progression.